Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Farmers selling stock, land as 'extreme' drought dries up streamsFascinating 'heat maps' reveal where in the world Brits think famous landmarks areBill disestablishing Māori Health Authority to go through Parliament under urgency todayHow to get around the great Easter flight ripMinistry of Education explains why it has hired so many new staffA silenced merryJoe Biden Inauguration: World hopes for renewed cooperation with US under BidenSnake on a plane! Footage captures the moment a SERPENT emerges above an overhead bin midChristopher Luxon leaves Big Gay Out after heated protestTravel influencer reveals genius hack for getting toddlers to sleep on flights
2.7238s , 6501.4453125 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Worldly Wonders news portal